AR056063A1 - Utilizacion de la agomelatina para la obtencion de medicamentos destinados al tratamiento de trastornos del sueno en el paciente deprimido - Google Patents

Utilizacion de la agomelatina para la obtencion de medicamentos destinados al tratamiento de trastornos del sueno en el paciente deprimido

Info

Publication number
AR056063A1
AR056063A1 ARP060103908A ARP060103908A AR056063A1 AR 056063 A1 AR056063 A1 AR 056063A1 AR P060103908 A ARP060103908 A AR P060103908A AR P060103908 A ARP060103908 A AR P060103908A AR 056063 A1 AR056063 A1 AR 056063A1
Authority
AR
Argentina
Prior art keywords
agomelatine
treatment
obtaining
disorders
medicines
Prior art date
Application number
ARP060103908A
Other languages
English (en)
Inventor
Bruno Delalleau
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36200255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR056063(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of AR056063A1 publication Critical patent/AR056063A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente se refiere a la utilizacion de agomelatina o N-[2-(7-metoxi-1-naftil)etil]acetamida para la obtencion de medicamentos destinados al tratamiento de trastornos del sueno en el paciente deprimido. Reivindicacion 2: Composiciones farmacéuticas caracterizadas porque contienen la agomelatina o N-[2-(7-metoxi-1-naftil)etil]acetamida o sus hidratos, formas cristalinas y sales de adicion con un ácido o base farmacéuticamente aceptable, sola o en combinacion con uno o varios excipientes farmacéuticamente aceptables.
ARP060103908A 2005-09-09 2006-09-08 Utilizacion de la agomelatina para la obtencion de medicamentos destinados al tratamiento de trastornos del sueno en el paciente deprimido AR056063A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0509207A FR2890562B1 (fr) 2005-09-09 2005-09-09 Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles du sommeil chez le patient deprime

Publications (1)

Publication Number Publication Date
AR056063A1 true AR056063A1 (es) 2007-09-19

Family

ID=36200255

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103908A AR056063A1 (es) 2005-09-09 2006-09-08 Utilizacion de la agomelatina para la obtencion de medicamentos destinados al tratamiento de trastornos del sueno en el paciente deprimido

Country Status (26)

Country Link
US (1) US20070060655A1 (es)
EP (2) EP1762237A1 (es)
JP (1) JP2007077148A (es)
KR (2) KR20070029608A (es)
CN (1) CN1927193B (es)
AP (1) AP2008004379A0 (es)
AR (1) AR056063A1 (es)
AU (1) AU2006209372A1 (es)
BR (1) BRPI0603762A (es)
CA (1) CA2558762A1 (es)
EA (1) EA014288B1 (es)
FR (1) FR2890562B1 (es)
GE (1) GEP20094602B (es)
GT (1) GT200600409A (es)
HK (1) HK1100481A1 (es)
MA (1) MA28506B1 (es)
MX (1) MXPA06010233A (es)
NO (1) NO20064050L (es)
NZ (1) NZ549726A (es)
PE (1) PE20070333A1 (es)
SG (1) SG146451A1 (es)
TW (1) TW200800148A (es)
UA (1) UA81573C2 (es)
UY (1) UY29777A1 (es)
WO (1) WO2007028905A1 (es)
ZA (1) ZA200607531B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2918370B1 (fr) * 2007-07-02 2009-08-28 Servier Lab Nouveaux derives naphtaleniques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2918372B1 (fr) * 2007-07-02 2009-08-28 Servier Lab Nouveaux derives naphtaleniques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN102190595A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀溴化氢水合物及其制备方法
CN102190594A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀氯化氢水合物及其制备方法
CN101991559B (zh) * 2010-11-25 2012-04-18 天津市汉康医药生物技术有限公司 一种稳定的阿戈美拉汀胶囊药物组合物
FR2978916B1 (fr) * 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
WO2013119605A1 (en) * 2012-02-07 2013-08-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Promoting sleep using at1 receptor blockers
CN102552211B (zh) * 2012-02-16 2013-07-17 福建广生堂药业股份有限公司 一种阿戈美拉汀的制剂组合物及其制备方法
PT2810656T (pt) 2013-06-06 2017-11-13 Zentiva As Formulações de agomelatina compreendendo agomelatina na forma de cocristais
EP2810647A1 (en) 2013-06-06 2014-12-10 Zentiva, a.s. Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid
EP2856934A1 (en) * 2013-10-04 2015-04-08 Les Laboratoires Servier Biomarkers for the prediction of long term remission in depression
CN103690499B (zh) * 2013-12-23 2015-05-06 天津泰普药品科技发展有限公司 一种稳定的晶i型阿戈美拉汀片剂及其制备方法
CN103655499B (zh) * 2013-12-23 2015-07-22 天津泰普药品科技发展有限公司 一种稳定的晶x型阿戈美拉汀片剂及其制备方法
CN104523639B (zh) * 2014-12-11 2017-03-22 扬子江药业集团四川海蓉药业有限公司 一种阿戈美拉汀片剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2834890B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'agomelatine
JP2007517040A (ja) * 2003-12-24 2007-06-28 セプレイコー インコーポレイテッド 睡眠の質を改善するためのメラトニン併用療法
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
US7645905B2 (en) * 2005-08-03 2010-01-12 Les Laboratoires Servier Crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it
US7358395B2 (en) * 2005-08-03 2008-04-15 Les Laboratories Servier Crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it
US7635721B2 (en) * 2005-08-03 2009-12-22 Les Laboratoires Servier Crystalline form III of agomelatine, a process for its preparation and pharmaceutical compositions containing it

Also Published As

Publication number Publication date
FR2890562A1 (fr) 2007-03-16
KR20070029608A (ko) 2007-03-14
NZ549726A (en) 2008-03-28
SG146451A1 (en) 2008-10-30
KR20080103043A (ko) 2008-11-26
EP2295050A1 (fr) 2011-03-16
GEP20094602B (en) 2009-02-10
GT200600409A (es) 2007-04-30
WO2007028905A1 (fr) 2007-03-15
AU2006209372A1 (en) 2007-03-29
JP2007077148A (ja) 2007-03-29
FR2890562B1 (fr) 2012-10-12
NO20064050L (no) 2007-03-12
EA014288B1 (ru) 2010-10-29
UA81573C2 (en) 2008-01-10
PE20070333A1 (es) 2007-06-02
CN1927193A (zh) 2007-03-14
MA28506B1 (fr) 2007-04-03
TW200800148A (en) 2008-01-01
HK1100481A1 (en) 2007-09-21
BRPI0603762A (pt) 2007-05-15
CA2558762A1 (fr) 2007-03-09
AP2008004379A0 (en) 2008-04-30
CN1927193B (zh) 2011-01-05
EA200601449A1 (ru) 2007-04-27
UY29777A1 (es) 2006-10-31
MXPA06010233A (es) 2007-03-08
EP1762237A1 (fr) 2007-03-14
US20070060655A1 (en) 2007-03-15
ZA200607531B (en) 2008-05-28

Similar Documents

Publication Publication Date Title
AR056063A1 (es) Utilizacion de la agomelatina para la obtencion de medicamentos destinados al tratamiento de trastornos del sueno en el paciente deprimido
CO5840252A1 (es) Utilizacion de la agomelatina para la obtencion de medicamentos destinados al tratamiento del trastorno de ansiedad generalizada
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
CL2007003009A1 (es) N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)piperidin-4-ilideno)metil)benzamida; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento del dolor, ansiedad y depresion.
UY29470A1 (es) Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos bipolares
HRP20110370T1 (hr) Uporaba agomelatina za dobivanje lijeka u cilju liječenja smith-magenisovog sindroma
AR080150A1 (es) Utilizacion de la agomelatina para la obtencion de medicamentos destinados al tratamiento del trastorno obsesivo compulsivo (toc)
ES2422877B1 (es) Combinación y composición para el tratamiento de obesidad
AR063895A1 (es) Utilizacion de la agomelatina para la obtencion de medicamentos destinados al tratamiento de la leucomalacia periventricular
CO6592037A2 (es) Combinación de un aine y un aminoacido
CU20070232A7 (es) Utilización de la agomelatina para la obtención de medicamentos destinados al tratamiento de los trastornos bipolares
TH85272B (th) การใช้อะโกเมลาทีนในการได้มาเป็นยาเวชภัณฑ์ที่มุ่งหมายเพื่อการบำบัดความผิดปกติของโรคไบโพลาร์
TH85272A (th) การใช้อะโกเมลาทีนในการได้มาเป็นยาเวชภัณฑ์ที่มุ่งหมายเพื่อการบำบัดความผิดปกติของโรคไบโพลาร์
EA200601450A1 (ru) Новая комбинация агомелатина и тиморегулирующего средства и фармацевтические композиции, которые её содержат
TH87502B (th) การใช้ของอะโกเมลาทีนในการได้รับเภสัชภัณฑ์ที่ถูกมุ่งหมายสำหรบการรักษาของความผิดปกติในการนอนหลับผู้ช่วยที่ซึมเศร้า
TH87500B (th) ความเกี่ยวข้องใหม่ระหว่างอะโกเมลาทีนและสารควบคุมต่อมไธมัสและสารผสมทางเภสัชกรรมที่มีสิ่งนี้
TH97711B (th) การใช้อะโกมีลาทีนในการทำให้มาถึงเวชภัณฑ์ที่มุ่งหมายสำหรับการรักษา Smith-Magenis ซินโดรม
CU20070070A7 (es) Composición farmacéutica de agomelatina
CL2007002789A1 (es) Forma cristalina de [2-(6-fluor-1h-indol-3-ilsulfanil)bencil]metilamina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos afectivos y depresivos, ansiedad, dolor.
TH87500A (th) ความเกี่ยวข้องใหม่ระหว่างอะโกเมลาทีนและสารควบคุมต่อมไธมัสและสารผสมทางเภสัชกรรมที่มีสิ่งนี้
TH99000B (th) การใช้อะโกมีลาทีนในการทำให้มาถึงเวชภัณฑ์ที่มุ่งหมายสำหรับการรักษาเพอริเวนตริคูลาร์ ลิวโคมาลาเซีย

Legal Events

Date Code Title Description
FA Abandonment or withdrawal